T-cell chronic lymphocytic leukemia
GPTKB entity
Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:affects |
T-cells
|
| gptkbp:associated_with |
gptkb:myelodysplastic_syndromes
gptkb:healthcare_organization immune system dysfunction chronic inflammation viral infections autoimmune disorders lymphoproliferative disorders secondary malignancies |
| gptkbp:clinical_trial |
ongoing
|
| https://www.w3.org/2000/01/rdf-schema#label |
T-cell chronic lymphocytic leukemia
|
| gptkbp:occurs_in |
rare
|
| gptkbp:research_focus |
quality of life
biomarkers genetic mutations new therapies survivorship issues treatment resistance |
| gptkbp:risk_factor |
age
family history exposure to certain chemicals |
| gptkbp:scientific_classification |
hematologic malignancy
|
| gptkbp:social_responsibility |
variable
blood tests flow cytometry imaging tests bone marrow biopsy |
| gptkbp:symptoms |
fatigue
weight loss fever bleeding joint pain neurological symptoms night sweats easy bruising skin rashes pallor increased infections enlarged lymph nodes |
| gptkbp:treatment |
gptkb:vaccine
palliative care rehabilitation services clinical trials combination therapy antibiotics nutritional support supportive care monoclonal antibodies radiation therapy chemotherapy psychosocial support targeted therapy pain management follow-up care stem cell transplant maintenance therapy antiviral therapy experimental therapies |
| gptkbp:type_of |
gptkb:prolymphocytic_leukemia
small cell leukemia |
| gptkbp:bfsParent |
gptkb:ALK
|
| gptkbp:bfsLayer |
5
|